Public Health and Economic Effects of Influenza Vaccination

Authors

  • Zirui Gao

DOI:

https://doi.org/10.61173/ke3h8d53

Keywords:

Influenza vaccination, health systems, economic impact, antiviral resistance

Abstract

Seasonal influenza constitutes a severe global health challenge, characterized by annual recurrence, millions of infections and substantial mortality each year. Its persistent circulation not only imposes heavy burdens on healthcare systems worldwide but also inflicts notable economic losses. Given the predictable nature of seasonal influenza outbreaks, long-term prevention strategies centered on vaccination have proven more effective in mitigating its impact compared to short-term control measures. This paper studies how vaccination policies work in different regions and how they affect health systems, economic costs, and antiviral resistance. Data from WHO, CDC, and other studies show that higher vaccination coverage clearly lowers infections, hospital stays, and deaths. Even small increases in coverage can prevent many cases. Vaccination also saves medical costs, keeps hospitals less crowded, and slows drug resistance by reducing antiviral use. However, problems such as vaccine hesitancy, low access in rural and low-income areas, and weak global surveillance still limit progress. To solve these issues, countries need clear communication, free or low-cost vaccination, stronger monitoring, and better government support. These actions can raise vaccination rates, make health systems more stable, and help the world prepare for future outbreaks.

References

[1] World Health Organization. (2025, February 28). Influenza (seasonal). World Health Organization. https://www.who.int/ news-room/fact-sheets/detail/influenza-(seasonal).

[2] Peasah, S. K., Azziz-Baumgartner, E., Breese, J., Meltzer, M. I., & Widdowson, M. A. (2013). Influenza cost and costeffectiveness studies globally: A review. Vaccine, 31(46), 5339– 5348. https://doi.org/10.1016/j.vaccine.2013.09.013.

[3] Goodfellow, L., Patel, R., Chen, Y., & Alvarez, M. (2025). The potential global health impact and cost-effectiveness of next-generation influenza vaccines. PLOS Medicine, 22(4), e1004655. https://doi.org/10.1371/journal.pmed.1004655.

[4] Centers for Disease Control and Prevention. (2024, September 20). Flu vaccination coverage, United States, 2023–24 influenza season. U.S. Department of Health and Human Services. https://www.cdc.gov/fluvaxview/coverage-byseason/2023-2024.html.

[5] Yang, J., Atkins, K. E., Feng, L., Pang, M., Zheng, Y., Liu, X., Cowling, B. J., & Yu, H. (2016). Seasonal influenza vaccination in China: Landscape of diverse regional reimbursement policy, and budget impact analysis. Vaccine, 34, 5724–5735. https://doi. org/10.1016/j.vaccine.2016.10.013.

[6] Centers for Disease Control and Prevention. (2025). Flu burden prevented by vaccination: 2023–2024 flu season. U.S. Department of Health and Human Services. https://www.cdc. gov/flu-burden/php/data-vis-vac/2023-2024-prevented.html.

[7] Hughes, M. M., Reed, C., Flannery, B., Garg, S., Singleton, J. A., Fry, A. M., & Rolfes, M. A. (2020). Projected population benefit of increased effectiveness and coverage of influenza vaccination on influenza burden in the United States. Clinical Infectious Diseases, 70(12), 2496–2502. https://doi.org/10.1093/ cid/ciz676.

[8] Molinari, N.-A. M., Ortega-Sanchez, I. R., Messonnier, M. L., Thompson, W. W., Wortley, P. M., Weintraub, E., & Bridges, C. B. (2007). The annual impact of seasonal influenza in the United States: Measuring disease burden and costs. Vaccine, 25(27), 5086–5096. https://doi.org/10.1016/j.vaccine.2007.03.046.

[9] Hayden, F. G., & de Jong, M. D. (2011). Emerging influenza antiviral resistance threats. Journal of Infectious Diseases, Dean&Francis ISSN 2959-409X 203(1), 6–10. https://doi.org/10.1093/infdis/jiq012.

[10] Hurt, A. C., & Kelly, H. (2016). Debate regarding oseltamivir use for seasonal and pandemic influenza. Emerging Infectious Diseases, 22(6), 949–955. https://doi.org/10.3201/ eid2206.151037.

[11] Dubé, E., Vivion, M., & MacDonald, N. E. (2015). Vaccine hesitancy: An overview. Human Vaccines & Immunotherapeutics, 9(8), 1763–1773. https://doi.org/10.4161/ hv.24657.

[12] Schmid, P., Rauber, D., Betsch, C., Lidolt, G., & Denker, M. L. (2017). Barriers of influenza vaccination intention and behavior – A systematic review of influenza vaccine hesitancy, 2005–2016. PLOS ONE, 12(1), e0170550. https://doi. org/10.1371/journal.pone.0170550.

Downloads

Published

2026-02-28